Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy

NCT00974311 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00974311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00974311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
November 2, 2017
Enrollment
1,199 (actual)
Sites
249

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer